Physician profile
Grace Lin
NPI 1114167178
$953.93
in general payments reported to CMS, 2019-2025
15 companies · $83.33 in 2025
The $83.33 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $39.35 · 2020: $22.49 · 2021: $85.77 · 2022: $127 · 2023: $310 · 2024: $286 · 2025: $83.33.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $679.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $679.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $345.95 | 2020-2024 | Lokelma, Farxiga |
| Otsuka America Pharmaceutical, INC. | $147.52 | 2023-2025 | Jynarque |
| Novartis Pharmaceuticals Corporation | $105.05 | 2024 | |
| Akebia Therapeutics INC | $84.35 | 2021-2022 | |
| Calliditas Therapeutics US INC. | $41.11 | 2024 | |
| Fresenius USA Marketing, INC. | $35.85 | 2024-2025 | Velphoro, Velphoro |
| Opko Pharmaceuticals, LLC | $29.21 | 2022 | |
| Aurinia Pharma U.S., INC. | $27.38 | 2021 | |
| Travere Therapeutics, INC. | $23.11 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.09 | 2025 | Jardiance |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $20.61 | 2019 | |
| Merck Sharp & Dohme LLC | $18.74 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.42 | 2021 | |
| Amgen INC. | $17.05 | 2025 | Tavneos |
| Glaxosmithkline, LLC. | $16.49 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Grace Lin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.